[Hyperthermic chemotherapy for peritoneal primary and gastrointestinal carcinomatoses]

K Slim; O Glehen; F N Gilly

doi:10.1016/j.anchir.2003.09.002

[Hyperthermic chemotherapy for peritoneal primary and gastrointestinal carcinomatoses]

Ann Chir. 2003 Nov;128(9):580-9. doi: 10.1016/j.anchir.2003.09.002.

[Article in French]

Authors

K Slim¹, O Glehen, F N Gilly

Affiliation

¹ Service de chirurgie générale et digestive, Hôtel-Dieu, boulevard Léon-Malfreyt, 63058, Clermont-Ferrand, cedex 1, France. [email protected]

PMID: 14659610
DOI: 10.1016/j.anchir.2003.09.002

Abstract

Peritoneal carcinomatosis should no longer be considered as an automatically terminal disease in abdominal cancer patients. The aim of this comprehensive review of the literature was to evaluate the indications and contraindications of intraperitoneal hyperthermic chemotherapy with extensive cytoreduction surgery. Several aspects of the procedure are detailed. Feasibility, short-term and survival results are analysed owing to a comprehensive review of published studies.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma / diagnosis
Carcinoma / mortality
Carcinoma / therapy*
Combined Modality Therapy
Contraindications
Feasibility Studies
Follow-Up Studies
Gastrointestinal Neoplasms / diagnosis
Gastrointestinal Neoplasms / mortality
Gastrointestinal Neoplasms / therapy*
Humans
Hyperthermia, Induced / adverse effects
Hyperthermia, Induced / methods*
Morbidity
Neoplasm Staging
Patient Selection
Peritoneal Neoplasms / diagnosis
Peritoneal Neoplasms / mortality
Peritoneal Neoplasms / therapy*
Prognosis
Proportional Hazards Models
Second-Look Surgery
Survival Analysis
Treatment Outcome